de Visser KE - Search Results

1

Coffelt SB, Wellenstein MD, de Visser KE. Coffelt SB, et al. Among authors: de visser ke. Nat Rev Cancer. 2016 Jul;16(7):431-46. doi: 10.1038/nrc.2016.52. Epub 2016 Jun 10. Nat Rev Cancer. 2016. PMID: 27282249 Review.

2

Identification of peptides for immunotherapy of cancer. It is worth the effort.

Velders MP, Nieland JD, Rudolf MP, Loviscek K, Weijzen S, de Visser KE, Macedo MF, Carbone M, Kast WM. Velders MP, et al. Among authors: de visser ke. Crit Rev Immunol. 1998;18(1-2):7-27. doi: 10.1615/critrevimmunol.v18.i1-2.30. Crit Rev Immunol. 1998. PMID: 9419444 Review.

3

Tumor size at the time of adoptive transfer determines whether tumor rejection occurs.

Cordaro TA, de Visser KE, Tirion FH, Graus YM, Haanen JB, Kioussis D, Kruisbeek AM. Cordaro TA, et al. Among authors: de visser ke. Eur J Immunol. 2000 May;30(5):1297-307. doi: 10.1002/(SICI)1521-4141(200005)30:5<1297::AID-IMMU1297>3.0.CO;2-C. Eur J Immunol. 2000. PMID: 10820375

4

Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection?

Cordaro TA, de Visser KE, Tirion FH, Schumacher TN, Kruisbeek AM. Cordaro TA, et al. Among authors: de visser ke. J Immunol. 2002 Jan 15;168(2):651-60. doi: 10.4049/jimmunol.168.2.651. J Immunol. 2002. PMID: 11777958

5

Circumventing T-cell tolerance to tumour antigens.

Kessels HW, de Visser KE, Kruisbeek AM, Schumacher TN. Kessels HW, et al. Among authors: de visser ke. Biologicals. 2001 Sep-Dec;29(3-4):277-83. doi: 10.1006/biol.2001.0300. Biologicals. 2001. PMID: 11851328

6

CD8+ T cell tolerance and cancer immunotherapy.

De Visser KE, Schumacher TN, Kruisbeek AM. De Visser KE, et al. J Immunother. 2003 Jan-Feb;26(1):1-11. doi: 10.1097/00002371-200301000-00001. J Immunother. 2003. PMID: 12514424 Review.

7

De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent.

de Visser KE, Korets LV, Coussens LM. de Visser KE, et al. Cancer Cell. 2005 May;7(5):411-23. doi: 10.1016/j.ccr.2005.04.014. Cancer Cell. 2005. PMID: 15894262

8

Paradoxical roles of the immune system during cancer development.

de Visser KE, Eichten A, Coussens LM. de Visser KE, et al. Nat Rev Cancer. 2006 Jan;6(1):24-37. doi: 10.1038/nrc1782. Nat Rev Cancer. 2006. PMID: 16397525 Review.

9

Inflammation, proteases and cancer.

van Kempen LC, de Visser KE, Coussens LM. van Kempen LC, et al. Among authors: de visser ke. Eur J Cancer. 2006 Apr;42(6):728-34. doi: 10.1016/j.ejca.2006.01.004. Epub 2006 Mar 9. Eur J Cancer. 2006. PMID: 16524717 Review.

10

Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.

Overwijk WW, de Visser KE, Tirion FH, de Jong LA, Pols TW, van der Velden YU, van den Boorn JG, Keller AM, Buurman WA, Theoret MR, Blom B, Restifo NP, Kruisbeek AM, Kastelein RA, Haanen JB. Overwijk WW, et al. Among authors: de jong la, de visser ke. J Immunol. 2006 May 1;176(9):5213-22. doi: 10.4049/jimmunol.176.9.5213. J Immunol. 2006. PMID: 16621986 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results